researched 72 / 72 ・ last checked 2026-09-23 ENJA
Japan8United States8Canada8European Union8United Kingdom8China8Australia8Korea8Switzerland8

Advertising AtlasCanada / Safety information

Safety information

Canada / Health Canada / PAAB

Risk information must be given prominence comparable to benefit in the main body copy, the advertising message must reference a safety profile consistent with the Terms of Market Authorization, and special warnings, precautions, clinically significant serious adverse events and use limitations must appear in the body copy.

広告本文ではリスク情報を便益と同等の目立ち方で示し、承認事項に沿った安全性プロファイルに言及し、特別な警告・注意・臨床的に重大な有害事象・使用制限を本文に記載しなければならない。

Note
PAAB is an independent self-regulatory preclearance body, not a government regulator; the Code binds materials submitted to PAAB. The PDF served at this URL carries the internal version line 'Version date: February 1, 2024'.
Every cell carries a summary, a source and a date checked. Topics whose source has not been verified are left marked “not researched” rather than filled with plausible text. Directives and statutes bind as to the result; what applies in practice is national implementing law. This is a research aid, not legal advice.